Helen Cho, Ph.D. Head of R&D

After earning her Bachelor’s degree from the Department of Biochemistry, Yonsei University and her Master’s degree in bioengineering from KAIST, Dr. Helen Cho acquired her PhD degree in molecular biology and biochemistry from the University of Medicine and Dentistry of New Jersey. Then, she completed her post-doctorate program at Salk Institute and joined Pfizer, a global pharmaceutical company, where she led the development of anticancer immunotherapy drugs based on combination therapy by using her experiences in various fields covering biological carriers and antibodies. As an Associate Research Fellow, she oversaw the research and development (R&D) of anticancer vaccines and oncolytic virus-based immunotherapy drugs as well as early clinical trials. Currently, she serves as the Director of Samyang Holdings Biopharmaceuticals Division R&D Center, supervising R&D in pharmaceuticals, biologics and MD businesses.

Scientific Advisory Board

Louis M. Weiner

Professor and Chairman
Department of Oncology Georgetown University Medical Center

Lombardi Comprehensive Cancer Center Georgetown University Medical Center

Thomas F. Gajewski

AbbVie Foundation Professor
Cancer Immunotherapy, Departments of Pathology, Medicine and the Ben May Department for Cancer Research

University of Chicago